Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | (FY)Jun 30, 2021 | (FY)Jun 30, 2020 | (FY)Jun 30, 2018 | (FY)Jun 30, 2017 | |
|---|---|---|---|---|---|---|---|---|
| Total revenue | -28.23%15.72M | -22.89%21.9M | -20.40%28.4M | 24.56%35.68M | 143.16%28.64M | 11.78M | 0.51%15.09M | 15.01M |
| Cost of revenue | 36.37%14.75M | -22.21%10.81M | -32.02%13.9M | 9.89%20.45M | 138.79%18.61M | 7.79M | 2.24%9.85M | 9.64M |
| Gross profit | -91.22%974K | -23.53%11.09M | -4.79%14.5M | 51.77%15.23M | 151.70%10.04M | 3.99M | -2.60%5.24M | 5.38M |
| Operating expense | 86.85%8.87M | -7.19%4.75M | 1.35%5.12M | 10.70%5.05M | -0.61%4.56M | 4.59M | 8.03%3.97M | 3.67M |
| Selling and administrative expenses | 74.60%9.03M | -8.00%5.17M | 2.44%5.62M | 14.24%5.49M | -1.91%4.8M | --4.9M | 7.50%4.12M | --3.83M |
| -Selling and marketing expense | -48.36%110K | -42.09%213K | -26.15%367.82K | 103.41%498.09K | 8.36%244.88K | --225.98K | -1.65%254.16K | --258.42K |
| -General and administrative expense | 79.89%8.92M | -5.61%4.96M | 5.30%5.25M | 9.45%4.99M | -2.41%4.56M | --4.67M | 8.16%3.87M | --3.57M |
| Total other operating income | -62.88%157K | -16.17%423K | 15.04%504.62K | 80.65%438.65K | -21.24%242.82K | --308.31K | -4.60%152.66K | --160.02K |
| Operating profit | -224.48%-7.9M | -32.43%6.34M | -7.83%9.39M | 85.96%10.18M | 1,013.07%5.48M | -599.83K | -25.54%1.27M | 1.7M |
| Net non-operating interest income (expenses) | 9.23%-246K | -4.79%-271K | -58.38%-258.62K | 25.18%-163.29K | 34.21%-218.25K | -331.72K | 25.70%-431.67K | -580.94K |
| Non-operating interest expense | -9.23%246K | 4.79%271K | 58.38%258.62K | -25.18%163.29K | -34.21%218.25K | --331.72K | -25.70%431.67K | --580.94K |
| Net investment income | ||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||
| Income from associates and other participating interests | ||||||||
| Special income (charges) | 30K | 0 | ||||||
| Less:Write off | ---- | ---- | ---- | ---- | ---- | ---- | ---30K | --0 |
| Other non-operating income (expenses) | ||||||||
| Income before tax | -234.09%-8.14M | -33.48%6.07M | -8.91%9.13M | 90.58%10.02M | 664.51%5.26M | -931.55K | -22.78%866.77K | 1.12M |
| Income tax | -100.13%-2K | -32.58%1.53M | -7.13%2.27M | 86.12%2.44M | 1,134.33%1.31M | 106.22K | 15.64%335.64K | 290.24K |
| Net income | -279.14%-8.14M | -33.78%4.54M | -9.49%6.86M | 92.05%7.58M | 480.39%3.95M | -1.04M | -36.18%531.12K | 832.22K |
| Net income continuous operations | -279.14%-8.14M | -33.78%4.54M | -9.49%6.86M | 92.05%7.58M | 480.39%3.95M | ---1.04M | -36.18%531.12K | --832.22K |
| Noncontrolling interests | ||||||||
| Net income attributable to the company | -279.14%-8.14M | -33.78%4.54M | -9.49%6.86M | 92.05%7.58M | 480.39%3.95M | -1.04M | -36.18%531.12K | 832.22K |
| Preferred stock dividends | ||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -279.14%-8.14M | -33.78%4.54M | -9.49%6.86M | 92.05%7.58M | 480.39%3.95M | -1.04M | -36.18%531.12K | 832.22K |
| Gross dividend payment | ||||||||
| Basic earnings per share | -279.22%-0.0923 | -33.80%0.0515 | -9.43%0.0778 | 92.17%0.0859 | 355.43%0.0447 | -0.0175 | -36.19%0.006 | 0.0094 |
| Diluted earnings per share | -279.22%-0.0923 | -33.80%0.0515 | -9.43%0.0778 | 92.17%0.0859 | 355.43%0.0447 | -0.0175 | -36.19%0.006 | 0.0094 |
| Dividend per share | -10.00%0.0045 | -66.67%0.005 | -10.71%0.015 | 271.76%0.0168 | 0.0045 | |||
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.